Bauer takes role of president at Chemwerth

Formerly with Sandoz

Jeffrey Bauer has taken over as president of ChemWerth, a US supplier of active pharmaceutical ingredients for generic medicines.

Prior to joining ChemWerth, Bauer was vice president of business development and licensing at Sandoz, a position that he held for five years beginning in 2005. At Sandoz, Bauer managed the US generic product portfolio as well as active pharmaceutical ingredient (API) sourcing and procurement.

Before Sandoz, Bauer worked at Eon Labs, a generic pharmaceutical company acquired by Sandoz in 2005. In total, Bauer has 18 years’ experience in the pharmaceutical and medical device industries.

ChemWerth was founded in 1982 to supply the emerging generic pharmaceutical industry with sources of high quality APIs. The firm represents numerous US FDA approved facilities in China, as well as a growing number of cGMP manufacturing facilities in the US, Europe and India.

You may also like

Manufacturing
The 7 most common process development mistakes

The 7 most common process development mistakes

At laboratory scale, processes may appear predictable, repeatable, and well understood. However this perceived level of control can be misleading
Regulatory
What is ISO/IEC 17025 and why it matters for calibration

What is ISO/IEC 17025 and why it matters for calibration

As regulatory expectations continue to increase, particularly around data integrity and traceability, the question becomes less about collecting data, and more about trusting it
Regulatory
NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development

NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development

The discussion underscored the growing importance of aligning employee behaviours with compliance objectives, while also addressing the industry’s ongoing challenges around regulatory benchmarking and operational consistency
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Neuland Laboratories announces new $20m process development lab in Hyderabad

Neuland Laboratories announces new $20m process development lab in Hyderabad

The new facility will be fully operational by October 2026 and will give clients earlier manufacturability insight when looking to scale up, through the incorporation of non-GMP kilo labs as well as AI-driven route scouting, parallel synthesis and ELNs
Regulatory
FDA approves Utebzi, first oral carbapenem antibiotic, for complicated UTIs

FDA approves Utebzi, first oral carbapenem antibiotic, for complicated UTIs

GSK and Spero Therapeutics' tebipenem pivoxil matches IV imipenem-cilastatin in Phase III trials, offering an outpatient alternative for resistant infections that cost the US healthcare system more than $6bn annually
Pharmaceutical
Maximising product recovery with a GFD filter dryer removable basket

Maximising product recovery with a GFD filter dryer removable basket

Product value is often inversely proportional to volume in pharmaceutical R&D and kilo-lab production. When synthesising a few hundred grams of a novel drug candidate, every milligram can represent weeks of experimentation, costly reagents, and the potential success of a clinical trial
Pharmaceutical
How pressure and vacuum filtration in ANFDs improves yield

How pressure and vacuum filtration in ANFDs improves yield

During solid-liquid separation in industries such as pharmaceuticals and fine chemicals, both process efficiency and product quality are critical requirements. Effective use of pressure and vacuum filtration can help address this in downstream processing
Subscribe now